原发性肝癌(primary liver cancer, PLC) 是我国常见的消化系统恶性肿瘤之一,
其主要病理类型为肝细胞癌(hepatocellular carcinoma, HCC). 目前HCC …

Background and Aims: Hepatitis B virus (HBV) reactivation can occur to 10–40% of
lymphoma patients with 'resolved'HBV infection (HBsAg-negative and anti-HBc-positive) …

免疫抑制状态下的HBV 感染者在接受化学治疗, 免疫抑制治疗或生物治疗时,
由于这些治疗影响患者自身免疫系统, 从而导致抗病毒的免疫功能受损, 使原本处于低活跃状态 …

There have been unique adverse events reported with targeted blockade of programmed
death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte …

Hepatitis B virus (HBV) reactivation induced by cytotoxic chemotherapy is an important issue
in cancer patients. An elevated HBV viral load usually precedes hepatitis flare, and hepatic …

Background The safety of immune‐checkpoint inhibitors (ICIs) has not been thoroughly
investigated in non–small cell lung cancer (NSCLC) patients with chronic hepatitis B (CHB) …

我国的乙型肝炎病毒(hepatitis B virus, HBV) 感染率一直居高不下, 许多罹患其他疾病的患者均
合并有HBV 感染, 在血液系统疾病中最常见的就是非霍奇金淋巴瘤(non-Hodgkin's lymphoma …

Background Immune checkpoint inhibitor (ICI)-related liver injury is a growing concern as
ICIs are increasingly used in cancer treatment regimens. Interestingly, ICIs have exhibited …

Background: Hepatocellular Carcinoma (HCC) is one of the most common cancers with high
mortality rate. The effects of most therapies are limited. The Immune Checkpoint Blockade …